• Neurocrine Biosciences Chief Legal Officer Darin Lippoldt exercised options to buy 10,000 common shares at USD 81.49 on July 9, 2026.
• He sold 10,000 common shares the same day at an average price of USD 179.6.
• He reported direct ownership of 54,729 common shares following the transactions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurocrine Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001504783-26-000017), on July 13, 2026, and is solely responsible for the information contained therein.